Sarah Boyce, President and CEO at Avidity Biosciences, Inc. (RNA), sold 112,000 shares at $22.63 ($2.4M) on 2024-03-12, disclosed to the SEC on 2024-03-12.
Scheduled sale ($2.4M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.39 | 84,000 | $1.8M | 73.9% |
| 2 | $22.63 | 28,000 | $634K | 26.1% |
| Total | $21.70 avg | 112,000 | $2.4M | 100% |
| Filing → |
| RNA | SELL | 2025-09-05 | $2.5M | — | Filing → |
| RNA | SELL | 2025-08-29 | $1.2M | — | Filing → |
| RNA | SELL | 2025-03-21 | $2.0M | — | Filing → |